Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | LIMK1 | P53667 | 3/20 | 0.41 |
| ▸ | CDC7 | O00311 | 2/20 | 0.41 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.41 |
| ▸ | CLK1 | P49759 | 2/20 | 0.41 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 5/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | KRAS | P01116 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8049644 | 0.76 | KDM4E (0.40) | KDM4EALDH1A1MCL1HPGDMAPK1 | |
| SCHEMBL8049628 | 0.75 | KRAS (0.43) | KDM4EALDH1A1MCL1HPGDMAPK1 | |
| SCHEMBL8049657 | 0.73 | MAPT (0.56) | KDM4EALDH1A1MCL1HPGDHTT | |
| SCHEMBL18552580 | 0.73 | KDM4E (0.42) | KDM4EALDH1A1MCL1HPGDMAPK1 | |
| SCHEMBL271817 | 0.72 | LIMK1 (0.41) | KDM4EALDH1A1HPGDHTTKMT2A | |
| SCHEMBL23378336 | 0.72 | LIMK1 (0.55) | KDM4EALDH1A1LIMK1CDC7DBF4 | |
| SCHEMBL11072002 | 0.70 | KDM4D (0.43) | ALDH1A1HPGDLIMK1NPC1LMNA | |
| SCHEMBL22006355 | 0.70 | DAO (0.42) | KDM4EALDH1A1MCL1CDC7DBF4 | |
| SCHEMBL14780491 | 0.70 | LIMK1 (0.53) | KDM4EHPGDLIMK1CDC7DBF4 | |
| SCHEMBL23378412 | 0.69 | LIMK1 (0.48) | KDM4EALDH1A1LIMK1CDC7DBF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1623987-A1 | Fused pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and pyrido[3',2':4,5]furo[3,2-d]pyrimidines | Curacyte Discovery GmbH (DE) | 2006-02-08 | — | — | EP | claimed |
| EP-1619197-A1 | Substituted Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1H,3H)diones and -4(3H)ones as well as Pyrido[3',2':4,5]furo[3,2-d]-pyrimidin-2,4(1H,3H)diones und -4(3H)ones as inhibitors of TNF-alpha release | Curacyte Discovery GmbH (DE) | 2006-01-25 | — | — | EP | claimed |
| US-6133275-A | ALPHA 1 ADRENORECEPTOR ANTAGONISTS; TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER UROLOGICAL DISEASES E.G., BLADDER OUTLET OBSTRUCTION), NEUROGENIC BLADDER AND GYNECOLOGICAL SYNDROMES, E.G., DYSMENORRHEA; UTERINE MUSCLE RELAXANTS | ABBOTT LABORATORIES (US) | 2000-10-17 | — | — | US | claimed |
| US-20190040079-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2019-02-07 | — | — | US | disclosed |
| US-20190040079-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2019-02-07 | — | — | US | disclosed |
| US-9938290-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938290-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938290-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20180009826-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2018-01-11 | — | — | US | disclosed |
| US-20180009826-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | CONVALIFE (SHANGHAI) CO. LIMITED (CN) | 2018-01-11 | — | — | US | disclosed |
| US-9580442-B2 | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors | KARUS THERAPEUTICS LIMITED (GB) | 2017-02-28 | — | — | US | disclosed |
| EP-1623987-A1 | Fused pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and pyrido[3',2':4,5]furo[3,2-d]pyrimidines | Curacyte Discovery GmbH (DE) | 2006-02-08 | — | — | EP | disclosed |
| EP-1623987-A1 | Fused pyrido[3',2':4,5]thieno[3,2-d]pyrimidines and pyrido[3',2':4,5]furo[3,2-d]pyrimidines | Curacyte Discovery GmbH (DE) | 2006-02-08 | — | — | EP | disclosed |
| WO-2006010568-A2 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, PYRIDO[3',2':4,5]FURO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, AND USE THEREOF AS INHIBITORS OF TNF-ALPHA RELEASE | CURACYTE DISCOVERY GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006010568-A2 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, PYRIDO[3',2':4,5]FURO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, AND USE THEREOF AS INHIBITORS OF TNF-ALPHA RELEASE | CURACYTE DISCOVERY GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006010568-A2 | SUBSTITUTED PYRIDO[3',2':4,5]THIENO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, PYRIDO[3',2':4,5]FURO[3,2-D]PYRIMIDINE-2,4(1 H,3H)-DIONES AND -4(3H)-ONES, AND USE THEREOF AS INHIBITORS OF TNF-ALPHA RELEASE | CURACYTE DISCOVERY GMBH (DE) | 2006-02-02 | — | — | WO | disclosed |
| EP-1619197-A1 | Substituted Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1H,3H)diones and -4(3H)ones as well as Pyrido[3',2':4,5]furo[3,2-d]-pyrimidin-2,4(1H,3H)diones und -4(3H)ones as inhibitors of TNF-alpha release | Curacyte Discovery GmbH (DE) | 2006-01-25 | — | — | EP | disclosed |
| EP-1619197-A1 | Substituted Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1H,3H)diones and -4(3H)ones as well as Pyrido[3',2':4,5]furo[3,2-d]-pyrimidin-2,4(1H,3H)diones und -4(3H)ones as inhibitors of TNF-alpha release | Curacyte Discovery GmbH (DE) | 2006-01-25 | — | — | EP | disclosed |
| EP-1619197-A1 | Substituted Pyrido[3',2':4,5]thieno[3,2-d]pyrimidin-2,4(1H,3H)diones and -4(3H)ones as well as Pyrido[3',2':4,5]furo[3,2-d]-pyrimidin-2,4(1H,3H)diones und -4(3H)ones as inhibitors of TNF-alpha release | Curacyte Discovery GmbH (DE) | 2006-01-25 | — | — | EP | disclosed |
| US-6133275-A | ALPHA 1 ADRENORECEPTOR ANTAGONISTS; TREATING BENIGN PROSTATIC HYPERPLASIA AND OTHER UROLOGICAL DISEASES E.G., BLADDER OUTLET OBSTRUCTION), NEUROGENIC BLADDER AND GYNECOLOGICAL SYNDROMES, E.G., DYSMENORRHEA; UTERINE MUSCLE RELAXANTS | ABBOTT LABORATORIES (US) | 2000-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009826-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3C2A | KDM4E 2632/4885ALDH1A1 4413/4885MCL1 1738/4885 |
| US-20190040079-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3R2 | KDM4E 2632/4885ALDH1A1 4341/4885MCL1 1741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.